
Researchers have isolated for the first time a free-floating form of amyloid beta that appears to be a key driver of Alzheimer’s disease. Further, they argue that a newly approved Alzheimer’s drug — lecanemab (Leqembi) — directly targets these small, complex chains of amyloid beta (A-beta) called fibrils. The U.S. Food and Drug Administration approved… read on > read on >